Abstract
Clinicians are risk-stratifying asthma and COPD exacerbations based on type 2 inflammatory biomarkers. Measurement of blood eosinophils and FENO have demonstrated promising results in identifying patients who would benefit from oral corticosteroids.
| Original language | English |
|---|---|
| Article number | 2500685 |
| Journal | European Respiratory Journal |
| Volume | 66 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Type 2 inflammatory biomarkers in asthma and COPD: what we think we know'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver